Posts Tagged ‘AIM-HIGH’

January 15th, 2013

Is HDL Fool’s Gold?

Peter P. Toth offers his perspective on recent trials of niacin, including HPS2-THRIVE and AIM-HIGH.

January 9th, 2013

Niacin Therapy in the Crossfire


William E. Boden, lead investigator of the AIM-HIGH trial, and CardioExchange’s Harlan M. Krumholz debate the current state of research on niacin therapy.

January 4th, 2013

Why Has Niacin Therapy Failed to THRIVE?


In the wake of HPS2-THRIVE, John Ryan asks William E. Boden, lead investigator of the AIM-HIGH trial, for his perspective on niacin and other HDL-modifying therapies.

December 20th, 2012

HPS2-THRIVE: No Benefit, Signal of Harm for Niacin Therapy

The largest-ever study of niacin has failed to show a clinical benefit of niacin and even found a strong signal of harm. Merck announced today that the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study did not meet its primary endpoint. In that study, the combination of a statin and Merck’s niacin compound, Tredaptive, a combination of extended-release niacin and […]

November 16th, 2011

Was AIM HIGH a Hit or a Miss?

One of the best parts of this conference has been the opportunity to hear experts on the panels dissect and interpret the data following the presentations.

November 15th, 2011

After AIM HIGH, What Future for Niacin? A CardioExchange Panel

Steve Nissen, JoAnne Foody, Roger Blumenthal, and AIM HIGH author William Boden weigh in on what patients do and don’t remain good candidates for niacin therapy.

May 26th, 2011

NHLBI Stops the AIM-HIGH Trial of Niacin

The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health) trial of niacin has been stopped early by the NHLBI. The trial was designed to test the addition of high-dose, extended-release niacin to statins in people at risk for CV events who had well-controlled LDL but low HDL and elevated […]